Compare Crispr Therapeutics AG (CRSP) vs LTC Properties Inc (LTC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs LTC Properties Inc — how do they compare? Crispr Therapeutics AG trades at $50.95 (market cap $5.06B), while LTC Properties Inc trades at $43.29 (market cap $2.25B). The key difference: Crispr Therapeutics AG is far larger — about 2.2× LTC Properties Inc's market cap, and LTC Properties Inc pays a 5.45% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and LTC Properties Inc for 89 Days on average.
| CRSP | LTC | |
|---|---|---|
Market Cap | $5.06B | $2.25B |
Volume | 1,678,371 | 1,238,557 |
Sector | Health | Real Estate |
52-Week High | $74.92 | $43.50 |
52-Week Low | $44.34 | $33.98 |
Typical Hold Time | 77 Days | 89 Days |
Enterprise Value | $3.48B | $2.99B |
Dividend Yield | — | 5.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $50.44, down 6.59% over 24 hours amid bearish technical signals. The company shows negative profitability metrics with -4,101.26% net income margin and -$581.60M net loss for 2025, though Q2 2026 EPS beat expectations. Recent news highlights upcoming clinical data presentations and commercial progress with CASGEVY gene therapy. Cash flow remains negative from operations but positive overall due to financing activities.
While analyst consensus remains bullish with 57.9% buy ratings and $67.83 price target, significant execution risks persist. The stock faces pressure from sustained cash burn and competitive threats, but potential catalysts include upcoming clinical data readouts and CASGEVY revenue growth. Investors should weigh high-risk biotech volatility against breakthrough therapy potential.
LTC Properties trades at $41.81, down 1.48% today, with mixed technical signals showing bullish moving averages but neutral oscillators. The REIT maintains strong profitability with 38.93% net margins and pays consistent monthly dividends of $0.19 per share. Recent acquisitions totaling $360 million accelerate the company's SHOP portfolio transformation, while analyst consensus targets $49.67 with 32% buy ratings.
LTC presents a balanced opportunity with demographic tailwinds in senior housing but faces execution risks from aggressive expansion. The stock trades at reasonable valuations (P/E 14.93) with upside to analyst targets, though rising interest rates and integration challenges warrant caution for the growth strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About LTC Properties Inc
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in healthcare facilities through mortgage loans, property lease transactions, and other investments. LTC generates all of its revenue in the United States. LTC is an active capital provider in the seniors housing and health care real estate industry. The company has been actively engaged with its operating partners to create a growing pipeline of projects. LTC considers merger and acquisition investment as a component of its operational growth strategy.
Read more on LTC →
